Discover novel immune checkpoint receptors

Cancer cells can avoid triggering an immune response by ‘switching off’ T-cells through inhibitory ligand-receptor interactions at immune checkpoints. Immuno-oncology therapies – using antibodies or recombinant forms of receptors or ligands – can disrupt these molecular checkpoints stimulating an anti-tumour response and potentially conferring long-term cancer immunity. As well as ultimately benefiting patients, the identification of novel immune checkpoint interactions presents a significant commercial advantage by opening up new targets for therapeutic development as well as furthering our understanding of their mechanisms of action.

Despite the recent surge in interest in this area, the molecular mechanisms for several key immune checkpoint interactions have yet to be elucidated. This is due in large part to the limitations of the standard techniques available.

Retrogenix has screened several key immune checkpoint molecules for clients, identifying novel receptors that are now the targets for the development of new immune checkpoint inhibitor therapies. Our results have also been used in patent applications to protect novel discoveries in this area.

See our case studies below for further details of how our cell microarray technology identifies immune checkpoint targets.

immune_checkpoint_cs

Case study: Compugen study identifies key TIGIT family immune checkpoint pair

Data presented at the 2016 Annual Meeting of the Society for the Immunotherapy of Cancer (SITC)  showcased the utility of the Retrogenix platform in identifying a key immune checkpoint pairing within the TIGIT family. This case study provides  details of how PVRL2 was identified as a specific cell surface binding partner for PVRIG which has presented new opportunities for the development of cancer immunotherapy treatments including potential combination therapies with current immune checkpoint blockers.

Read more

Case study: Using the Retrogenix technology to uncover immune checkpoint receptors

Discover novel immune checkpoint receptors

Many key immune checkpoint interactions are not yet fully characterised – hampering efforts to discover and develop new, targeted immuno-therapies. Results from Retrogenix’s plasma membrane protein array screening demonstrate an efficient method for rapidly identifying specific ligand-receptor binding in human cells.

Read more

Talk to us about a project
Please leave this field empty.
Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
We are very happy with our collaboration with Retrogenix, and how their platform has delivered.
Dr. Björn Frendéus, Vice President of Pre-clinical Research at BioInvent International A/B